Share
DNA science. Artificial intelligence. Smartphones and 3D printers. Science and technology have transformed the world we live in. But how did we get here? It wasn’t by accident. Well, sometimes it was. It was also the result of hard work, teamwork, and competition. And incredibly surprising moments. Hosted by bestselling author Steven Johnson (“How We Got To Now”), American Innovations uses immersive scenes to tell the stories of the scientists, engineers, and ordinary people behind the great ...
…
continue reading
Manage episode 518728129 series 2134816
Content provided by Bryn Mawr Communications (BMC) and Retina Today. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Bryn Mawr Communications (BMC) and Retina Today or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Could a biologic that addresses uveitic macular edema (UME) change the treatment landscape for uveitis patients? Rahul Khurana, MD, joins us to review data from the MEERKAT and SANDCAT trials assessing vamikibart (Genentech/Roche) for UME. And Arshad Khanani, MD, MA, joins us to review the open-label extension study of GATHER2. What effect does avacincaptad pegol (Izervay, Astellas) have 2 years after the initial study was completed? Join us to hear details about these late-breaking presentations from AAO 2025.
218 episodes
))
